OncoInsight

Insightful breakthrough medicine for immune cell therapy

Seoul, South Korea · Founded 2020 · $21.2M raised

Headquarters
Seoul
Employees
11–50
Founded
2020
Business Model
B2B
Total Funding
$21.2M
Last Round
$21.2M Series A
Rounds
1

About

OncoInsight is a South Korean biotechnology company developing advanced allogeneic immune cell therapies for cancer treatment. The company's pipeline includes UCB-NK cell therapy for breast cancer, CAR-NK cell therapy for gastric cancer, iPSC-derived NK cells, CAR macrophage therapies for solid tumors, and HSC-derived CAR-NK cells for B cell-driven autoimmune diseases such as lupus. OncoInsight also uses humanized mice as preclinical tools for human-specific studies. The company's mission is to discover, develop, and deliver novel off-the-shelf NK cell therapy product candidates that have a profound impact on cancer patients, aiming to become the leading company in accessible cell therapies.

Summary

OncoInsight is a Biotech company based in Seoul, South Korea, founded in 2020. It has raised $21.2M in total across 1 round. Investors include KB Securities and SBI Investment.

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Series ASeries A
$21.2M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

OncoInsight on Indexed.vc
<a href="https://indexed.vc/companies/oncoinsight"><img src="https://indexed.vc/api/badge/company/oncoinsight" alt="OncoInsight on Indexed.vc" width="260" height="76" /></a>